Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

$90.2M

Market Cap • 2/4/2025

2021

(4 years)
Founded

2024

(1 year ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Cranford

Headquarters • New York